CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Therapeutics, a clinical stage biotechnology company pioneering messenger RNA (mRNA) Therapeutics™ to create a new generation of transformative medicines for patients, announced today the appointment of Annie Seibold Drapeau as Chief Human Resources Officer. In her new role, Ms. Drapeau will lead Moderna’s talent and organizational strategy to support its continued growth and advancement of its mRNA drug pipeline. She currently serves as an Operating Partner at Bain Capital Private Equity, where she partners with companies across the private equity portfolio on a range of talent and organizational capability initiatives. Ms. Drapeau will join Moderna in late October and be a member of the company’s executive committee, reporting to Moderna CEO Stéphane Bancel.
“We are thrilled to welcome Annie to lead human resources; her role will be critical to Moderna’s future and success,” said Mr. Bancel. “Annie is a highly respected thought leader in building strong organizations across various sectors. She is well positioned to help us tailor an organizational and talent strategy that aligns with our unique culture, business model and our vision to impact many lives around the world with a new class of mRNA medicines. I had the chance to spend a lot of time with Annie throughout the course of the interview process, and I am looking forward to having her on the Moderna executive committee.”
“I’m very excited to join the Moderna team, particularly at this critical juncture for the company,” said Ms. Drapeau. “As Moderna continues its evolution as a clinical stage company with a fully integrated manufacturing facility to be built in Norwood, I’ll be focused on working across the organization to ensure the necessary capabilities are in place to support the company’s growth. It’s clear that Moderna’s success has been driven by its incredibly talented and passionate people. As Moderna continues to make amazing progress, I look forward to partnering with my colleagues to ensure we preserve and nurture this unique culture that inspires people to do exciting and truly transformational work each day.”
Prior to joining Bain Capital Private Equity, Ms. Drapeau served as Executive Vice President, Strategy and Talent at Iron Mountain, a $3 billion data storage and protection business with nearly 20,000 employees worldwide. She had responsibility for corporate strategy, human resources and the company’s portfolio of emerging business opportunities. She also led the company’s diversity and sustainability efforts. Before joining Iron Mountain, Ms. Drapeau held leadership roles in human resources, strategy and finance at the Center for Leading Organizations, VistaPrint, Digitas, PepsiCo and JPMorgan. She has been published in the Harvard Business Review on the topic of trust and leadership, and also led a session on that topic at the Annual Meeting of the World Economic Forum in Davos. Ms. Drapeau holds a bachelor’s in chemical engineering from Bucknell University and an MBA from the Amos Tuck School at Dartmouth College. She chairs the Boston Advisory Board of Directors for the Posse Foundation, sits on the Alumni Association Board of Directors at Bucknell University and is a Trustee of the Nashoba Brooks School.
Earlier this month, Moderna announced plans to build a 200,000 square foot, fully integrated GMP mRNA clinical manufacturing facility in Norwood, Mass., to support and manage its anticipated breadth of clinical studies across its portfolio. Set to open in early 2018, the facility will employ approximately 100 of Moderna’s current 460 team members. In addition, Moderna plans to hire more than 100 new employees for the site.
About Moderna Therapeutics
Moderna is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, Elpidera, focused on rare diseases, and Caperna, focused on personalized cancer vaccines. Founded by Flagship VentureLabs™, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca, Alexion Pharmaceuticals, Merck and Vertex Pharmaceuticals. To learn more, visit www.modernatx.com.